Europe Gene Therapy Market

Europe Gene Therapy Market Overview:

The Europe gene therapy market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.3 Billion by 2033, exhibiting a growth rate (CAGR) of 12% during 2025-2033. The significant advancements in gene editing technologies, escalating prevalence of genetic disorders, increasing investment in research and development (R&D) activities, and favorable regulatory policies represent some of the key factors driving the market. Europe is home to leading research institutions and universities driving advancements in gene therapy, with more than 250 ongoing clinical trials focused on cell and gene therapies across the region.

Gene therapy refers to a pioneering medical technique designed to treat or prevent diseases by modifying genes in the body’s cells. It involves the introduction, removal, or alteration of genetic material within a patient’s cells to correct defective genes responsible for disease development. Gene therapy is comprised of several components, including the therapeutic deoxyribonucleic acid (DNA) itself, a vector to deliver the DNA into cells, and various gene manipulation techniques, such as clustered regularly interspaced short palindromic repeats (CRISPR). It is extensively used in the treatment of cancers, viral infections, cardiovascular diseases (CVDs), neurological disorders, autoimmune diseases, age-related diseases, certain forms of blindness, and genetic disorders, such as hemophilia, sickle cell disease, and cystic fibrosis. Gene therapy is a highly effective treatment option that offers cures for diseases currently untreatable, reduces healthcare expenditure over the long term, minimizes the burden of disease on patients and families, and improves patients' quality of life.

Europe Gene Therapy Market Trends:

Expanding Role of Biopharmaceutical Companies

Biopharmaceutical firms in Germany gene therapy market are increasing their involvement in research, clinical trials, and partnerships. These companies are investing heavily in infrastructure, manufacturing capabilities, and strategic alliances to accelerate product development. The rise in collaborations with research institutes and startups is helping translate early-stage innovations into market-ready treatments. Mergers and acquisitions have also become common as larger companies aim to strengthen their pipelines by acquiring promising candidates. The growing presence of biopharma players is creating a competitive environment that fuels faster approvals and broader patient access. This momentum is expected to significantly boost the availability and commercialization of advanced therapy medicinal product (ATMP) treatments across Europe in the coming years.

Breakthroughs in Gene Therapy Technologies

Ongoing advances in gene-editing tools, viral vectors, and delivery mechanisms are shaping gene therapy in Europe. Improvements in CRISPR-based editing, adeno-associated virus (AAV) vectors, and non-viral delivery methods are making treatments more precise, safer, and scalable. Many companies are focusing on optimizing vector design to minimize immune responses and enhance long-term efficacy. In addition, automation and digital technologies are helping streamline production, reducing costs, and enabling wider access. These technological developments are expanding the scope of treatable conditions, from rare inherited disorders to common diseases. The pace of innovation continues to redefine therapeutic possibilities and supports stronger regulatory confidence in approving novel therapies in the UK gene therapy market.

Rising Burden of Genetic Disorders and Cancers

Italy gene therapy market is witnessing a steady increase in genetic diseases and cancer cases, fueling demand for advanced treatment options. Conditions such as hemophilia, spinal muscular atrophy, and inherited retinal disorders are becoming key focus areas for therapy developers. At the same time, gene-based approaches are gaining ground in oncology, where they are being explored for both solid tumors and blood cancers. The growing prevalence of these conditions highlights the unmet medical need, driving healthcare systems and governments to support innovative treatment pathways. This rising disease burden is not only expanding the potential patient pool but also encouraging greater investment from the biotech sector and faster adoption of therapies across the region.

Europe Gene Therapy Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the Europe gene therapy market report, along with forecasts at the regional and country levels for 2025-2033. Our report has categorized the market based on gene type, vector type, delivery method, and application.

Gene Type Insights:

To get more information on this market, Request Sample

• Antigen
• Cytokine
• Tumor Suppressor
• Suicide Gene
• Deficiency
• Growth Factors
• Receptors
• Others

The report has provided a detailed breakup and analysis of the market based on gene type. This includes antigen, cytokine, tumor suppressor, suicide gene, deficiency, growth factors, receptors, and others.

Vector Type Insights: 

• Viral Vector
  • Adenoviruses
  • Lentiviruses
  • Retroviruses
  • Adeno-Associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • Vaccinia Virus
  • Others
• Non-Viral Techniques
  • Naked and Plasmid Vectors
  • Gene Gun
  • Electroporation
  • Lipofection
  • Others

A detailed breakup and analysis of the market based on the vector type has also been provided in the report. This includes viral vector (adenoviruses, lentiviruses, retroviruses, adeno-associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others) and non-viral techniques (naked and plasmid vectors, gene gun, electroporation, lipofection, and others).

Delivery Method Insights:

• In-Vivo Gene Therapy
• Ex-Vivo Gene Therapy

The report has provided a detailed breakup and analysis of the market based on the delivery method. This includes in-vivo and ex-vivo gene therapy.

Application Insights:

• Oncological Disorders
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Disease
• Others

The report has provided a detailed breakup and analysis of the market based on the application. This includes oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and others.

Country Insights:

• Germany
• France
• United Kingdom
• Italy
• Spain
• Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Germany, France, the United Kingdom, Italy, Spain, and others.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Europe Gene Therapy Market News:

• In May 2025, EMA’s Committee for Medicinal Products for Human Use gave a positive opinion recommending conditional marketing authorization in the EU for Aucatzyl (obecabtagene autoleucel), meant to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukemia in adults. It received EU authorization in July 2025.
• In November 2024, Genethon announced plans to launch a Phase 3 trial of its Duchenne muscular dystrophy gene therapy, GNT0004, in Europe. Early trial data showed boys receiving higher doses maintained or improved motor function. The results, presented at the ASGCT Breakthroughs in Muscular Dystrophy conference in Chicago, would guide the pivotal study. If positive, the company aims to seek regulatory approvals in Europe and the US.

Europe Gene Therapy Market Report Coverage:

Key Benefits for Stakeholders:

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Europe gene therapy market from 2019-2033.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the Europe gene therapy market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Europe gene therapy industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.